Skip to main content
Premium Trial:

Request an Annual Quote

Plexera Signs Early-Access Customer for ProteomicProcessor


NEW YORK (GenomeWeb News) - Plexera said today it has inked an agreement with an undisclosed early-access customer for its antibody discovery system, which it expects to launch in May 2008. 
 
Plexera said the partner, a therapeutic antibody company, intends to purchase one of the ProteomicProcessor Systems when the platform is commercially available.
 
The company said the system combines surface plasmon resonance technology with microarray multiplex capabilities to detect and monitor biomolecular binding kinetics for as many as 5,000 antigen-antibody interactions in one run.
 
Plexera, a subsidiary of Lumera, said its platform combines antibody screening and analysis of binding properties, concentration, and kinetics into a single process that can help speed up drug discovery research.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more